• Prevention of vein graft failure after coronary artery bypass graft (CABG) surgery is significant unmet clinical need with no FDA-approved solutions.
• CABG surgery remains the gold-standard treatment for patients with multivessel coronary artery disease, and the majority of CABG patients receive vein grafts.
• Vein graft failure occurs at alarmingly high rates, with 25% failure within 12-18 months and 50% failure within 5-10 years.
• Biograft is developing novel medical devices to significantly reduce vein graft failure and improve overall patient outcomes for patients undergoing CABG procedures.